Condyloma-Pipeline- Review-2021

Report Code: PMI460821 | Publish Date: February 2021 | No. of Pages: 132

Condyloma Pipeline Review 2021 Overview

Condyloma- Pipeline Review

Condyloma is the medical term which is also known as genital warts or anogenital warts. It denotes to an epidermal manifestation indorsed to the epidermotropic human papillomavirus (HPV). Genital warts can form on the skin on the inside or outside of vagina or anus, or inside the cervix. Genital warts are soft and has noncancerous growths. In most of the cases they can also be found on the mouth, lips, throat, and tongue.

It’s one of the most common sexually transmitted infections. Whereas, in adults genital warts are mainly spread by sexual contact, but in children they may also be transmitted through nonsexual ways, such as from an infected mother to her infant or through direct manual contact. However, if a child is suffering from genital warts there is the possibility of sexual abuse or early sexual activity. The disease is highly transmissible, even though no warts are noticeable. The period of incubation may vary from several weeks or months.

Pharmaceutical companies are focusing on launching drugs to treat Condyloma. For instance, in June 2018, Merck & Co., Inc. declared that the U.S. Food and Drug Administration (FDA) has known for review a new supplemental Biologics License Application (sBLA) for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), the company’s 9-valent HPV vaccine. The submission is looking for approval of an expanded age indication for GARDASIL 9 for use in women and men ages 27 to 45 for the prevention of certain diseases and cancers caused by the nine human papillomavirus (HPV) types covered by the vaccine.

Approximately 70% of pipeline drugs for Condyloma are in phase 1 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Condyloma.

Report Description

The report on Condyloma- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Condyloma. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

  • Assessment of pipeline products based on various stages of devolvement.
  • Provides an overview of the global therapeutic landscape of Condyloma (Infectious Disease).
  • Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
  • The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
  • Latest news, articles, press-release, and related conferences.


Condyloma Pipeline Review 2021 Key Issues Addressed


  • Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
  • Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
  • Build strategic initiatives by understanding the focus areas of leading companies
  • Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Condyloma Pipeline Review 2021 Table of Contents


  •  Introduction
  • Objectives of the Study
  • Definition
  • Report Overview
  • Condyloma Overview
  1. Executive Summary
  2. Condyloma: Pipeline Assessment
  • Company Overview
  • Product Description
  • Status
  • Phase
  • Study Design
  • Route of Administration
  • Indication       
  • Condition        
  • NCT Number              
  • Sponsor          
  • Collaborator   
  • Brief Title         
  • Study Start Date         
  • Study completion (Estimated/Actual)
  • Study Completion Date
  • Enrollment     
  • Research Location (Listed Location Countries)
  1. Condyloma: Analysis on Dormant & Discontinued Pipeline Candidates
  • Overview
  • Product Description
  • Reason for Discontinuation
  1. Condyloma: Additional Key Insights
  • Epidemiology Overview: Condyloma
  1. Condyloma: Press Releases, Latest News and Conference Details


  • Table of Content is tentative and subject to change as the research progresses
  • The drug candidates are included as examples in the pipeline when this ToC was designed and their status might have changed since then.